Authors
Liangliang Du, Yuwei Dai, Jiayu Sui, Yuwen Liao, Yonghe Liu, Liusi Du, Douyun Zeng
Published in
Endocrine research. Pages 1-14. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
This study investigated the anti-tumor efficacy of ononin in thyroid cancer (TC) and its molecular mechanisms.
In vitro, TPC-1 and IHH-4 cells treated with ononin were assessed for proliferation, apoptosis, global m5C levels, and the NSUN6-SKP2 interaction. A xenograft mouse model was used for in vivo validation.
Ononin suppressed TC cell proliferation, induced apoptosis, and reduced NSUN6-mediated m5C modification. Mechanistically, NSUN6 directly bound SKP2 mRNA and deposited m5C at site 2576, enhancing its stability. Overexpression of NSUN6 or SKP2 reversed ononin's anti-tumor effects. In vivo, ononin inhibited tumor growth without significant toxicity to normal thyroid epithelial cells or major mouse organs.
Ononin exerts anti-TC activity via the NSUN6/SKP2 axis, identifying NSUN6 as a potential therapeutic target and ononin as a candidate compound for TC worthy of further clinical investigation.
PMID:
43015002
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0